Target Information

Target General Information

Top

Target ID

T96144 (Former ID: TTDS00080)

Target Name

DNA topoisomerase II (TOP2)

Synonyms

TOP2; DNA topoisomerase 2

Click to Show/Hide

Gene Name

TOP2A; TOP2B

Target Type

Successful target

[1]

Disease

[+] 15 Target-related Diseases

Acute myeloid leukaemia [ICD-11: 2A60]

Anogenital warts [ICD-11: 1A95]

Bacterial infection [ICD-11: 1A00-1C4Z]

Bladder cancer [ICD-11: 2C94]

Breast cancer [ICD-11: 2C60-2C6Y]

Chemoprotection [ICD-11: N.A.]

Common warts [ICD-11: 1E80]

Gonococcal infection [ICD-11: 1A70-1A7Z]

HIV-infected patients with tuberculosis [ICD-11: 1B10-1B14]

Mature B-cell lymphoma [ICD-11: 2A85]

Otitis externa [ICD-11: AA00-AA13]

Otitis media [ICD-11: AA80-AB0Z]

Solid tumour/cancer [ICD-11: 2A00-2F9Z]

Syphilis [ICD-11: 1A61-1A6Z]

Urinary tract infection [ICD-11: GC08]

Function

Cut both strands of the DNA helix simultaneously in order to manage DNA tangles and supercoils.

Click to Show/Hide

BioChemical Class

ATP-hydrolyzing DNA topoisomerase

UniProt ID

TOP2A_HUMAN ; TOP2B_HUMAN

Sequence

MEVSPLQPVNENMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTYIGSVELVTQQ
MWVYDEDVGINYREVTFVPGLYKIFDEILVNAADNKQRDPKMSCIRVTIDPENNLISIWN
NGKGIPVVEHKVEKMYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVE
TASREYKKMFKQTWMDNMGRAGEMELKPFNGEDYTCITFQPDLSKFKMQSLDKDIVALMV
RRAYDIAGSTKDVKVFLNGNKLPVKGFRSYVDMYLKDKLDETGNSLKVIHEQVNHRWEVC
LTMSEKGFQQISFVNSIATSKGGRHVDYVADQIVTKLVDVVKKKNKGGVAVKAHQVKNHM
WIFVNALIENPTFDSQTKENMTLQPKSFGSTCQLSEKFIKAAIGCGIVESILNWVKFKAQ
VQLNKKCSAVKHNRIKGIPKLDDANDAGGRNSTECTLILTEGDSAKTLAVSGLGVVGRDK
YGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKNYEDEDSLKTLRYGKIMIMT
DQDQDGSHIKGLLINFIHHNWPSLLRHRFLEEFITPIVKVSKNKQEMAFYSLPEFEEWKS
STPNHKKWKVKYYKGLGTSTSKEAKEYFADMKRHRIQFKYSGPEDDAAISLAFSKKQIDD
RKEWLTNFMEDRRQRKLLGLPEDYLYGQTTTYLTYNDFINKELILFSNSDNERSIPSMVD
GLKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSSYHHGEMSLMMTIINLAQNFVGSNN
LNLLQPIGQFGTRLHGGKDSASPRYIFTMLSSLARLLFPPKDDHTLKFLYDDNQRVEPEW
YIPIIPMVLINGAEGIGTGWSCKIPNFDVREIVNNIRRLMDGEEPLPMLPSYKNFKGTIE
ELAPNQYVISGEVAILNSTTIEISELPVRTWTQTYKEQVLEPMLNGTEKTPPLITDYREY
HTDTTVKFVVKMTEEKLAEAERVGLHKVFKLQTSLTCNSMVLFDHVGCLKKYDTVLDILR
DFFELRLKYYGLRKEWLLGMLGAESAKLNNQARFILEKIDGKIIIENKPKKELIKVLIQR
GYDSDPVKAWKEAQQKVPDEEENEESDNEKETEKSDSVTDSGPTFNYLLDMPLWYLTKEK
KDELCRLRNEKEQELDTLKRKSPSDLWKEDLATFIEELEAVEAKEKQDEQVGLPGKGGKA
KGKKTQMAEVLPSPRGQRVIPRITIEMKAEAEKKNKKKIKNENTEGSPQEDGVELEGLKQ
RLEKKQKREPGTKTKKQTTLAFKPIKKGKKRNPWSDSESDRSSDESNFDVPPRETEPRRA
ATKTKFTMDLDSDEDFSDFDEKTDDEDFVPSDASPPKTKTSPKLSNKELKPQKSVVSDLE
ADDVKGSVPLSSSPPATHFPDETEITNPVPKKNVTVKKTAAKSQSSTSTTGAKKRAAPKG
TKRDPALNSGVSQKPDPAKTKNRRKRKPSTSDDSDSNFEKIVSKAVTSKKSKGESDDFHM
DFDSAVAPRAKSVRAKKPIKYLEESDEDDLF

Click to Show/Hide

Drugs and Modes of Action

Top

Approved Drug(s)

[+] 22 Approved Drugs

Aclarubicin

Drug Info

Approved

Acute myeloid leukaemia

[3], [4]

Amsacrine

Drug Info

Approved

Acute lymphoblastic leukaemia

[5]

Cinoxacin

Drug Info

Approved

Urinary tract infection

[4], [6]

Ciprofloxacin+dexamethasone

Drug Info

Approved

Otitis externa

[7]

Dexrazoxane

Drug Info

Approved

Breast cancer

[8], [9]

Dhaq diacetate

Drug Info

Approved

Solid tumour/cancer

[10]

Doxorubicin

Drug Info

Approved

Solid tumour/cancer

[3], [11]

Enoxacin

Drug Info

Approved

Urinary tract infection

[4], [12]

Epirubicin

Drug Info

Approved

Solid tumour/cancer

[13]

Etoposide

Drug Info

Approved

Solid tumour/cancer

[3], [14]

Fleroxacin

Drug Info

Approved

Bacterial infection

[15]

Idarubicin

Drug Info

Approved

Acute myeloid leukaemia

[13], [16]

Lomefloxacin

Drug Info

Approved

Bacterial infection

[17]

Lucanthone

Drug Info

Approved

Solid tumour/cancer

[18]

Mitoxantrone

Drug Info

Approved

Solid tumour/cancer

[19], [20]

Nalidixic Acid

Drug Info

Approved

Urinary tract infection

[4], [21]

Novobiocin

Drug Info

Approved

Bacterial infection

[22]

Pefloxacin

Drug Info

Approved

Gonococcal urethritis

[23]

Podofilox

Drug Info

Approved

External genital and perianal wart

[4]

Rosoxacin

Drug Info

Approved

Bacterial infection

[24]

Teniposide

Drug Info

Approved

Acute lymphoblastic leukaemia

[3], [25]

Valrubicin

Drug Info

Approved

Bladder cancer

[3]

Clinical Trial Drug(s)

[+] 25 Clinical Trial Drugs

Aldoxorubicin

Drug Info

Phase 3

Soft tissue sarcoma

[26], [27]

GSK2140944

Drug Info

Phase 3

Urinary tract infection

[28]

Pixantrone

Drug Info

Phase 3

Multiple sclerosis

[29], [30]

SNS-595

Drug Info

Phase 3

Acute myeloid leukaemia

[31]

Tirapazamine

Drug Info

Phase 3

Alzheimer disease

[32]

13-DEOXYADRIAMYCIN HYDROCHLORIDE

Drug Info

Phase 2

Solid tumour/cancer

[34]

Berubicin

Drug Info

Phase 2

Solid tumour/cancer

[35]

CAP-7.1

Drug Info

Phase 2

Solid tumour/cancer

[36]

Doxorubicin-eluting beads

Drug Info

Phase 2

Liver cancer

[37]

Elsamitrucin

Drug Info

Phase 2

Solid tumour/cancer

[38]

GPX-150D

Drug Info

Phase 2

Breast cancer

[39]

PYRAZOLOACRIDINE

Drug Info

Phase 2

Colorectal cancer

[40]

Sabarubicin

Drug Info

Phase 2

Solid tumour/cancer

[41]

Salvicine

Drug Info

Phase 2

Solid tumour/cancer

[42]

XR-5000

Drug Info

Phase 2

Colorectal cancer

[43]

F-14512

Drug Info

Phase 1/2

Solid tumour/cancer

[44]

L-377202

Drug Info

Phase 1/2

Solid tumour/cancer

[45]

BMY-43748

Drug Info

Phase 1

Bacterial infection

[48]

Daniquidone

Drug Info

Phase 1

Lymphoma

[49]

GRC-6211

Drug Info

Phase 1

Asthma

[50]

Iboctadekin + Doxil

Drug Info

Phase 1

Ovarian cancer

[51], [52]

NK-314

Drug Info

Phase 1

Solid tumour/cancer

[53]

Tafluposide

Drug Info

Phase 1

Solid tumour/cancer

[54]

TAS-103

Drug Info

Phase 1

Solid tumour/cancer

[55]

XR-5944

Drug Info

Phase 1

Gastric adenocarcinoma

[56]

Discontinued Drug(s)

[+] 17 Discontinued Drugs

BW-773U82

Drug Info

Discontinued in Phase 2

Solid tumour/cancer

[57]

ELINAFIDE MESILATE

Drug Info

Discontinued in Phase 2

Solid tumour/cancer

[58]

GL-331

Drug Info

Discontinued in Phase 2

Colorectal cancer

[59]

KW-2170

Drug Info

Discontinued in Phase 2

Breast cancer

[60]

LOSOXANTRONE

Drug Info

Discontinued in Phase 2

Breast cancer

[61]

Merbarone

Drug Info

Discontinued in Phase 2

Pancreatic cancer

[62]

Mitonafide

Drug Info

Discontinued in Phase 2

Solid tumour/cancer

[63]

NC-190

Drug Info

Discontinued in Phase 2

Solid tumour/cancer

[64]

SUPER-LEU-DOX

Drug Info

Discontinued in Phase 2

Solid tumour/cancer

[65]

Banoxantrone

Drug Info

Discontinued in Phase 1

Acute lymphoblastic leukaemia

[66]

Teloxantrone

Drug Info

Discontinued in Phase 1

Solid tumour/cancer

[67]

TOP-53

Drug Info

Discontinued in Phase 1

Metastatic lung cancer

[68]

A-74932

Drug Info

Terminated

Lung cancer

[70]

BE-22179

Drug Info

Terminated

leukaemia

[71]

Datelliptium chloride

Drug Info

Terminated

Breast cancer

[72]

Doxorubicin-CEA conjugate

Drug Info

Terminated

Breast cancer

[73]

Garenoxacin

Drug Info

Terminated

Endocarditis

[74]

Preclinical Drug(s)

[+] 1 Preclinical Drugs

Nemorubicin

Drug Info

Preclinical

Solid tumour/cancer

[69]

Mode of Action

[+] 4 Modes of Action

Inhibitor

[+] 46 Inhibitor drugs

Aclarubicin

Drug Info

[75], [76]

Amsacrine

Drug Info

[1]

Cinoxacin

Drug Info

[77]

Dhaq diacetate

Drug Info

[10], [78]

Enoxacin

Drug Info

[79]

Fleroxacin

Drug Info

[81]

Lomefloxacin

Drug Info

[82]

Lucanthone

Drug Info

[83]

Nalidixic Acid

Drug Info

[85]

Novobiocin

Drug Info

[86]

Pefloxacin

Drug Info

[79]

Rosoxacin

Drug Info

[89]

Valrubicin

Drug Info

[90]

GSK2140944

Drug Info

[92]

GRC-6211

Drug Info

[85]

Iboctadekin + Doxil

Drug Info

[99]

Amifloxacin

Drug Info

[85]

ELINAFIDE MESILATE

Drug Info

[4], [104]

A-62176

Drug Info

[116]

ER-37328

Drug Info

[120]

Garenoxacin

Drug Info

[121]

1,3,7-trihydroxyacridone

Drug Info

[76]

1-Methoxy-3-(oxiran-2-ylmethoxy)-9H-xanthen-9-one

Drug Info

[122]

2-(2-Aminoethyl)anthra[1,9-cd]pyrazol-6(2H)-one

Drug Info

[123]

2-(2-Hydroxyethyl)anthra[1,9-cd]pyrazol-6(2H)-one

Drug Info

[123]

3,3'-(4-phenylpyridine-2,6-diyl)diphenol

Drug Info

[124]

3-(2,6-diphenylpyridin-4-yl)phenol

Drug Info

[124]

3-(2-phenyl-6-(thiophen-2-yl)pyridin-4-yl)-phenol

Drug Info

[124]

3-(4-phenyl-6-(thiophen-2-yl)pyridin-2-yl)-phenol

Drug Info

[124]

3-(4-phenyl-6-(thiophen-3-yl)pyridin-2-yl)-phenol

Drug Info

[124]

3-(6-(furan-2-yl)-4-phenylpyridin-2-yl)-phenol

Drug Info

[124]

4'-Demethyl-4beta-amino-4-desoxypodophyllotoxin

Drug Info

[125]

4'-Demethyl-epipodophyllotoxin

Drug Info

[125]

4,4'-(4-phenylpyridine-2,6-diyl)diphenol

Drug Info

[124]

4-(furan-3-yl)-2,6-di(thiophen-2-yl)pyridine

Drug Info

[126]

7-chloro-1,3-dihydroxyacridone

Drug Info

[76]

AMP-PNP

Drug Info

[128]

Clorobiocin

Drug Info

[129]

DEMETHYLZEYLASTERONE

Drug Info

[130]

Ellipticine

Drug Info

[132]

Howiinol A (GHM-10)

Drug Info

[133]

ICRF-154

Drug Info

[134]

LUPEOL

Drug Info

[135]

Makaluvamine N

Drug Info

[136]

Olean-12-en-3beta,15alpha-diol

Drug Info

[135]

TOPOSTATIN

Drug Info

[137]

Binder

[+] 1 Binder drugs

Ciprofloxacin+dexamethasone

Drug Info

[7]

Modulator

[+] 48 Modulator drugs

Dexrazoxane

Drug Info

[2]

Doxorubicin

Drug Info

[2]

Epirubicin

Drug Info

[2]

Etoposide

Drug Info

[80]

Idarubicin

Drug Info

[2]

Mitoxantrone

Drug Info

[84]

Podofilox

Drug Info

[87], [88]

Teniposide

Drug Info

[2]

Aldoxorubicin

Drug Info

[91]

Pixantrone

Drug Info

[91]

SNS-595

Drug Info

[93]

Tirapazamine

Drug Info

[91]

13-DEOXYADRIAMYCIN HYDROCHLORIDE

Drug Info

[91]

Berubicin

Drug Info

[91]

CAP-7.1

Drug Info

[91]

Doxorubicin-eluting beads

Drug Info

[91]

Elsamitrucin

Drug Info

[38]

GPX-150D

Drug Info

[94]

PYRAZOLOACRIDINE

Drug Info

[95]

Sabarubicin

Drug Info

[91]

Salvicine

Drug Info

[42], [96]

XR-5000

Drug Info

[43]

F-14512

Drug Info

[97]

L-377202

Drug Info

[91]

BMY-43748

Drug Info

[4], [48]

Daniquidone

Drug Info

[98]

NK-314

Drug Info

[100]

Tafluposide

Drug Info

[101]

TAS-103

Drug Info

[102]

XR-5944

Drug Info

[56]

BW-773U82

Drug Info

[103]

GL-331

Drug Info

[105], [106]

KW-2170

Drug Info

[107]

LOSOXANTRONE

Drug Info

[108]

Merbarone

Drug Info

[109]

Mitonafide

Drug Info

[110]

NC-190

Drug Info

[111], [112]

SUPER-LEU-DOX

Drug Info

[91]

Banoxantrone

Drug Info

[91]

Teloxantrone

Drug Info

[113]

TOP-53

Drug Info

[114]

Nemorubicin

Drug Info

[115]

A-74932

Drug Info

[117]

BE-22179

Drug Info

[118]

Datelliptium chloride

Drug Info

[119]

Doxorubicin-CEA conjugate

Drug Info

[2]

doxorubicin-LL2 conjugate

Drug Info

[131]

doxorubicin-peptide-PEG conjugate

Drug Info

[131]

Intercalator

[+] 1 Intercalator drugs

Ametantrone

Drug Info

[127]

Chemical Structure based Activity Landscape of Target

Top

Drug Property Profile of Target

Top

(1) Molecular Weight (mw) based Drug Clustering

(2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering

(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering

(4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering

(5) Rotatable Bond Count (rotbonds) based Drug Clustering

(6) Topological Polar Surface Area (polararea) based Drug Clustering

"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five

Co-Targets

Top

Co-Targets

Co-Targets Info

Target Poor or Non Binders

Top

Target Poor or Non Binders

Target Poor or Non Binders Info

Target-Related Models and Studies

Top

Target Validation

Target Validation Info

Target QSAR Model

References

Top

REF 1

Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 2000 Dec;15(6):413-21.

REF 2

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.

REF 3

Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.

REF 4

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

REF 5

Identification of FDA-approved drugs and bioactives that protect hair cells in the zebrafish (Danio rerio) lateral line and mouse (Mus musculus) ut... J Assoc Res Otolaryngol. 2009 Jun;10(2):191-203.

REF 6

FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018067.

REF 7

Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64.

REF 8

URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7330).

REF 9

FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076068.

REF 10

The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res. 2009 Feb 1;69(3):940-7.

REF 11

REF 12

FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019616.

REF 13

New drugs for the treatment of cancer, 1990-2001. Isr Med Assoc J. 2002 Dec;4(12):1124-31.

REF 14

REF 15

Drug information of Fleroxacin, Health Canada, 2007.

REF 16

REF 17

FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020013.

REF 18

Drug information of Lucanthone, 2008. eduDrugs.

REF 19

REF 20

Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis. J Neurol Sci. 2008 Oct 15;273(1-2):144-7.

REF 21

FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 071919.

REF 22

How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.

REF 23

Drug information of Pefloxacin, 2008. eduDrugs.

REF 24

Drug information of Rosoxacin, 2008. eduDrugs.

REF 25

REF 26

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 27

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 28

ClinicalTrials.gov (NCT04020341) A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI). U.S. National Institutes of Health.

REF 29

REF 30

ClinicalTrials.gov (NCT00088530) BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL). U.S. National Institutes of Health.

REF 31

ClinicalTrials.gov (NCT01191801) Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML (VALOR). U.S. National Institutes of Health.

REF 32

ClinicalTrials.gov (NCT00262821) Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer. U.S. National Institutes of Health.

REF 33

ClinicalTrials.gov (NCT00034333) Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer. U.S. National Institutes of Health.

REF 34

ClinicalTrials.gov (NCT00123877) Study of GPX-100 in the Treatment of Metastatic Breast Cancer. U.S. National Institutes of Health.

REF 35

ClinicalTrials.gov (NCT00538343) RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases. U.S. National Institutes of Health.

REF 36

ClinicalTrials.gov (NCT02094560) CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors. U.S. National Institutes of Health.

REF 37

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026037)

REF 38

Elsamicin A binding to DNA. A comparative thermodynamic characterization. FEBS Lett. 2004 Oct 8;576(1-2):68-72.

REF 39

ClinicalTrials.gov (NCT02267083) Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma. U.S. National Institutes of Health.

REF 40

ClinicalTrials.gov (NCT00003802) Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma. U.S. National Institutes of Health.

REF 41

ClinicalTrials.gov (NCT00027781) MEN-10755 in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy. U.S. National Institutes of Health.

REF 42

Salvicine functions as novel topoisomerase II poison by binding to ATP pocket. Mol Pharmacol. 2006 Nov;70(5):1593-601.

REF 43

Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol. 2002 May;13(5):777-80.

REF 44

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026777)

REF 45

ClinicalTrials.gov (NCT00987753) Study Evaluating the Safety and Tolerability of L-377202. U.S. National Institutes of Health.

REF 46

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009728)

REF 47

In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs. 2002 Jan;13(1):15-28.

REF 48

Comparative metabolism of tosufloxacin and BMY 43748 in hepatocytes from rat, dog, monkey and man. Toxicol In Vitro. 1993 Jul;7(4):499-503.

REF 49

ClinicalTrials.gov (NCT00450502) Safety of Batracylin in Patients With Solid Tumors and Lymphomas. U.S. National Institutes of Health.

REF 50

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024886)

REF 51

Clinical pipeline report, company report or official report of GlaxoSmithKline.

REF 52

ClinicalTrials.gov (NCT00659178) Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer. U.S. National Institutes of Health.

REF 53

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020174)

REF 54

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012192)

REF 55

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007714)

REF 56

Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs. 2001 Apr;12(4):359-67.

REF 57

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002707)

REF 58

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005099)

REF 59

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002538)

REF 60

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004178)

REF 61

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000754)

REF 62

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000894)

REF 63

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002671)

REF 64

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000904)

REF 65

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009260)

REF 66

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004590)

REF 67

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000732)

REF 68

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004663)

REF 69

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012041)

REF 70

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003878)

REF 71

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004286)

REF 72

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001278)

REF 73

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007194)

REF 74

Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.

REF 75

Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines. Anticancer Drug Des. 2001 Dec;16(6):305-15.

REF 76

1,3-Dihydroxyacridone derivatives as inhibitors of herpes virus replication. Antiviral Res. 2000 Feb;45(2):123-34.

REF 77

The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7.

REF 78

Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells. J Biol Chem. 2000 Aug 18;275(33):25231-8.

REF 79

Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.

REF 80

Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.

REF 81

Fleroxacin overview. Chemotherapy. 1996 Mar;42 Suppl 1:1-9.

REF 82

Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.

REF 83

Clonogenicity of human leukemic cells protected from cell-lethal agents by heat shock protein 70. Cell Stress Chaperones. 2005 Spring;10(1):37-45.

REF 84

Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.

REF 85

Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6.

REF 86

Transcriptional responses of Bacillus subtillis and thuringiensis to antibiotics and anti-tumour drugs. Int J Mol Med. 2009 Jan;23(1):33-9.

REF 87

Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.

REF 88

Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs.PLoS One.2013 Sep 20;8(9):e75252.

REF 89

Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids. Antimicrob Agents Chemother. 1986 Apr;29(4):598-601.

REF 90

Metabolic activation of N-acylanthracyclines precedes their interaction with DNA topoisomerase II. NCI Monogr. 1987;(4):111-5.

REF 91

Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

REF 92

Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent. J Clin Microbiol. 2014 Jul;52(7):2629-32.

REF 93

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.Haematologica.2015 Feb;100(2):231-7.

REF 94

Company report (Gem pharmaceuticals)

REF 95

Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res. 1998 Mar;4(3):683-91.

REF 96

Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation. Acta Pharmacol Sin. 2007 Sep;28(9):1460-5.

REF 97

Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II.Apoptosis.2012 Apr;17(4):364-76.

REF 98

Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.Cancer Chemother Pharmacol.2013 Oct;72(4):917-23.

REF 99

Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).

REF 100

NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J Biol Chem. 2008 Aug 29;283(35):23711-20.

REF 101

Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer. Anticancer Drugs. 2003 Jul;14(6):467-73.

REF 102

Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells. Cancer Chemother Pharmacol. 2000;45(1):78-84.

REF 103

Correlation of cytotoxicity and protein-associated DNA strand breaks for 2-(arylmethylamino)-1,3-propanediols. Anticancer Drug Des. 1998 Oct;13(7):825-35.

REF 104

Solution structure and dynamics of a complex between DNA and the antitumor bisnaphthalimide LU-79553: intercalated ring flipping on the millisecond time scale. Biochemistry. 1999 Nov 16;38(46):15104-15.

REF 105

GL331, a topoisomerase II inhibitor, induces radiosensitization of human glioma cells. Anticancer Res. 2006 May-Jun;26(3A):2149-56.

REF 106

Induction of apoptosis and cell cycle arrest in glioma cells by GL331 (a topoisomerase II inhibitor). Anticancer Res. 2005 Nov-Dec;25(6B):4203-8.

REF 107

KW-2170 (Kyowa Hakko Kogyo). IDrugs. 2002 Oct;5(10):1000-3.

REF 108

A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone. J Chem Inf Model. 2006 Jul-Aug;46(4):1827-35.

REF 109

The DNA topoisomerase II catalytic inhibitor merbarone is genotoxic and induces endoreduplication. Mutat Res. 2012 Oct-Nov;738-739:45-51.

REF 110

Effect of mitonafide analogs on topoisomerase II of Leishmania chagasi. Antimicrob Agents Chemother. 1996 Mar;40(3):706-9.

REF 111

The topoisomerase II-inhibitor NC-190 reduces the level of thymidine kinase mRNA in murine tumor cells. Res Commun Mol Pathol Pharmacol. 2002;111(1-4):77-87.

REF 112

A novel antitumor compound, NC-190, induces topoisomerase II-dependent DNA cleavage and DNA fragmentation. Cancer Chemother Pharmacol. 1996;38(1):29-34.

REF 113

Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical... J Natl Cancer Inst. 1994 Aug 17;86(16):1239-44.

REF 114

DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action. Biochemistry. 2001 Jan 23;40(3):712-8.

REF 115

The interaction of nemorubicin metabolite PNU-159682 with DNA fragments d(CGTACG)(2), d(CGATCG)(2) and d(CGCGCG)(2) shows a strong but reversible binding to G:C base pairs. Bioorg Med Chem. 2012 Dec 15;20(24):6979-88.

REF 116

Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model. J Med Chem. 1998 Oct 22;41(22):4273-8.

REF 117

Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical-induced clastogenicity in Chinese hamster V79 cells. Environ Mol Mutagen. 2000;35(1):13-21.

REF 118

A new topoisomerase II inhibitor, BE-22179, produced by a streptomycete. I. Producing strain, fermentation, isolation and biological activity. J Antibiot (Tokyo). 1994 Feb;47(2):129-35.

REF 119

Toxicity of the antitumoral drug datelliptium in hepatic cells: Use of models in vitro for the prediction of toxicity in vivo. Toxicol In Vitro. 1992 Jul;6(4):295-302.

REF 120

Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor. Mol Cancer Ther. 2002 Jan;1(3):169-75.

REF 121

The inhibition and selectivity of bacterial topoisomerases by BMS-284756 and its analogues. J Antimicrob Chemother. 2001 Aug;48(2):195-201.

REF 122

Synthesis and pharmacological evaluation of new methyloxiranylmethoxyxanthone analogues. Eur J Med Chem. 2010 Sep;45(9):4221-8.

REF 123

Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer... Bioorg Med Chem. 2010 Jun 1;18(11):3974-84.

REF 124

Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77.

REF 125

Antitumor agents, 107. New cytotoxic 4-alkylamino analogues of 4'-demethyl-epipodophyllotoxin as inhibitors of human DNA topoisomerase II. J Nat Prod. 1989 May-Jun;52(3):606-13.

REF 126

2,6-Dithienyl-4-furyl pyridines: Synthesis, topoisomerase I and II inhibition, cytotoxicity, structure-activity relationship, and docking study. Bioorg Med Chem Lett. 2010 Jan 1;20(1):42-7.

REF 127

Interactions of antitumor agents Ametantrone and Mitoxantrone (Novatrone) with double-stranded DNA. Biochem Pharmacol. 1985 Dec 15;34(24):4203-13.

REF 128

The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

REF 129

The high-resolution crystal structure of a 24-kDa gyrase B fragment from E.coli complexed with one of the most potent coumarin inhibitors, clorobiocin. Proteins. 1997 May;28(1):41-52.

REF 130

Catalytic inhibition of topoisomerase IIalpha by demethylzeylasterone, a 6-oxophenolic triterpenoid from Kokoona zeylanica. J Nat Prod. 2001 Oct;64(10):1294-6.

REF 131

The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.

REF 132

In vitro sensitivity of Trichomonas vaginalis to DNA topoisomerase II inhibitors. Southeast Asian J Trop Med Public Health. 2000 Mar;31(1):118-22.

REF 133

Anticancer effect of Howiinol A and its mechanism of action. J Asian Nat Prod Res. 1999;2(1):1-19.

REF 134

The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia. Exp Hematol. 2002 Nov;30(11):1273-82.

REF 135

Screening of triterpenoids isolated from Phyllanthus flexuosus for DNA topoisomerase inhibitory activity. J Nat Prod. 2001 Dec;64(12):1545-7.

REF 136

Makaluvamine N: a new pyrroloiminoquinone from Zyzzya fuliginosa. J Nat Prod. 1997 Apr;60(4):408-10.

REF 137

Isoaurostatin, a novel topoisomerase inhibitor produced by Thermomonospora alba. J Nat Prod. 2001 Feb;64(2):204-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Yuzong CHEN

Prof. Feng ZHU